Add time:07/16/2019         Source:sciencedirect.com

The in vitro metabolism of an inverse agonist of the peripheral cannabinoid receptor (CB2), indomethacin morpholinylamide (BML-190), has been characterized using rat liver microsomal incubation. BML-190 was found to yield at least 15 metabolic products as identified by HPLC–MS/MS analysis. Four major phase one metabolic pathways either individually, or in combination, were proposed to account for the identified metabolic products: (1) loss of the p-chlorobenzyl group, (2) hydroxylation on the indole or on the morpholine ring, (3) morpholinyl ring opening, and (4) demethylation of the methoxyl group on the indole ring.

We also recommend Trading Suppliers and Manufacturers of BML-190 (cas 2854-32-2). Pls Click Website Link as below: cas 2854-32-2 suppliers